Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) primarily used in the treatment of obsessive–compulsive disorder (OCD), depression, and various anxiety disorders, where it works by increasing serotonin levels in the brain to help regulate mood and behavior. It was first developed in the 1970s by Solvay Pharmaceuticals and later introduced into clinical use in the 1980s, becoming one of the earliest SSRIs to be marketed, particularly for OCD. Over time, fluvoxamine gained recognition for its efficacy in managing anxiety-related conditions and has been approved in many countries for both psychiatric and off-label uses; it is now marketed under brand names such as Luvox and continues to be an important option in psychopharmacology due to its established safety profile and therapeutic effectiveness.
BRAND NAMES
Fluvoxamine is most commonly marketed under the brand name Luvox, including its extended-release form Luvox CR. It is an SSRI primarily used to treat obsessive-compulsive disorder (OCD). Internationally, it is also available under other brand names such as Faverin, Voxamin, and Floxyfral, as well as in generic forms.
MECHANISM OF ACTION
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) used mainly to treat depression and obsessive-compulsive disorder (OCD). It works by inhibiting the serotonin reuptake transporter (SERT), thereby increasing serotonin levels in the brain. Additionally, it acts as a strong sigma-1 receptor agonist and shows minimal interaction with other receptor types.
PHARMACOKINETICS
Absorption: Fluvoxamine is well absorbed after oral administration, though it undergoes first-pass metabolism, resulting in moderate bioavailability. Peak plasma levels are usually reached within 3–8 hours.
Distribution: It is widely distributed throughout the body and moderately bound to plasma proteins (about 80%).
Metabolism: The drug is extensively metabolized in the liver, mainly via CYP enzymes such as CYP1A2 and CYP2D6, producing inactive metabolites.
Elimination: Fluvoxamine and its metabolites are primarily excreted in the urine.
PHARMACODYNAMICS
Fluvoxamine is a potent and highly selective serotonin reuptake inhibitor (SSRI) mainly used to treat OCD and depression. It works by blocking the serotonin transporter (SERT), thereby increasing serotonin (5-HT) levels in the brain. It also has a strong affinity for sigma-1 (σ₁) receptors, which may contribute to anti-inflammatory and neuroprotective effects, while having minimal influence on norepinephrine and dopamine, making it a highly selective medication.
ADMINISTRATION
Fluvoxamine is taken orally, available in immediate-release and extended-release (CR) tablets. Extended-release tablets are usually taken once daily at bedtime, while immediate-release tablets may be taken once or twice daily, depending on the condition and individual response. The tablets should be taken whole with water and may be taken either with or without food. Treatment typically begins with a low dose, which is gradually increased to reduce the risk of side effects.
DOSAGE AND STRENGTH
Fluvoxamine is prescribed in oral form, available as immediate-release and extended-release (CR) tablets. Typical starting doses for adults range from 50 mg to 100 mg daily, with gradual titration based on therapeutic response and tolerance. The maximum recommended daily dose is usually 300 mg for immediate-release and 300 mg for extended-release formulations. Tablets come in various strengths, commonly 25 mg, 50 mg, 100 mg, and 150 mg, allowing for flexible dosing adjustments.
DRUG INTERACTIONS
Fluvoxamine has several clinically significant drug interactions, mainly because it strongly inhibits CYP1A2 and CYP2C19 enzymes. It should not be combined with medications such as tizanidine, thioridazine, alosetron, or pimozide due to the risk of serious toxicity. Fluvoxamine can also increase blood levels of clozapine, theophylline, warfarin, and certain antidepressants or opioids. Additionally, co-administration with MAO inhibitors carries a high risk of serotonin syndrome.
FOOD INTERACTIONS
Fluvoxamine can interact with alcohol, caffeine, and foods high in tyramine, potentially leading to increased side effects such as severe dizziness, excessive drowsiness, or dangerous spikes in blood pressure. To reduce nausea, it is recommended to take the medication with or after meals. Alcohol and high-caffeine products should be avoided or limited during treatment.
CONTRAINDICATIONS
Fluvoxamine is contraindicated in combination with MAO inhibitors (such as linezolid or selegiline) because of the risk of potentially fatal serotonin syndrome, necessitating a 14-day washout period. It should also not be used with tizanidine, thioridazine, pimozide, alosetron, terfenadine, or astemizole due to the risk of severe adverse reactions, and is contraindicated in individuals with a known hypersensitivity to the drug.
SIDE EFFECTS
Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) primarily used to treat OCD and depression, commonly causes side effects such as nausea, drowsiness (somnolence), headache, and sexual dysfunction. Rare but serious risks include serotonin syndrome, bleeding complications, heightened suicidal thoughts in young adults, and withdrawal symptoms if the medication is stopped abruptly.
OVER DOSE
An overdose of fluvoxamine is a serious medical condition that requires immediate attention. Symptoms may include nausea, vomiting, dizziness, drowsiness, rapid or irregular heartbeat, and in severe cases, seizures or coma. Management is mainly supportive, as there is no specific antidote, and prompt medical care is essential.
TOXICITY
Fluvoxamine generally exhibits low acute toxicity when taken alone and has a wider safety margin compared to older antidepressants, with severe symptoms in overdose being uncommon. Typical overdose effects may include drowsiness, nausea, vomiting, abdominal pain, tremors, rapid heartbeat (tachycardia), and dizziness. Serious complications, such as seizures or coma, are rare and usually occur only at very high doses (greater than 1500 mg).
